IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented;...
Cancer
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk...
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create...
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
Dr. De La Rosa adds over 20 years of big pharma and biotech infectious disease clinical trial experience to Curevo...
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies...
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company...
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today...
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN...
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Phase 1b study builds on highly consistent preclinical and Phase 1a dataFort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) --...
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18th...
Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company,...
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
Barbara Klencke, M.D. Dr. Klencke is an accomplished oncology drug developer with a demonstrated track record of success, having made...
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Mainz Biomed Provides Full Year 2022 Financial Results
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April...
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and...
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose...
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed...
One Community, One Question: What Is Your #MYelomaSTORY?
The International Myeloma Foundation Reached Over 41 Million in More Than 45 Countries During 2023 Myeloma Action Month!STUDIO CITY, Calif.,...
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to...